One of the companies in the healthcare space to have done remarkable work in the research and development aspect of the business in recent times is Halberd Corporation (OTCMKTS:HALB). It is a company that may well be worth tracking at this point in time due to some of the strides it has made.
On Friday, HNRC stock fell 1% to $0.0107 with 1.222 million shares, compared to its average volume of 1.71 million shares. The stock moved within a range of $0.0102 – 0.0119 after opening trading at $0.0109.
The stock is traded on the OTC Markets and currently, it is completely compliant with the regulations. Back in April of 2020, the company had actually been restructured and since then it has managed to get exclusive global rights for as many as three patents. Additionally, it has also filed as many as 22 patent applications in the same period in order to further boost its value and also for attractive interest from potential developmental partners.
Last month on August 23, Halberd was in focus after it made a key announcement with regards to one of its latest research projects. The company announced that its team of researchers had managed to demonstrate that it could control the PD-1 levels in human blood serum to a precise degree. The demonstration had been done in an in-vitro laboratory testing environment. It is a significant development for Halberd since if PD-1 levels could be regulated then it would be possible for the body to fight cancerous tumors far more effectively.
At this point in time, many pharmaceutical companies are working on ways to produce a medicine that could control PD-1 levels thoroughly. The extracorporeal process from Halberd is meant for ensuring that the PD-1 levels remain at a healthy level and can be restored in a matter of hours. In this regard, it ought to be noted that the restoration of PD-1 levels in such a short period of time is particularly important since in the case of other medicines it can take many days or months.
HALB stock is trading below the 20-Day and 50-Day Moving averages of $0.0112 and $0.0124. Moreover, the stock is trading below the 200-Day moving average of $0.0176.